Key patent includes claims on haptics, MR compatibility and
WINNIPEG, May 22, 2013 /CNW/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM)
("IMRIS" or the "Company") today announced the allowance of a US patent
defining the foundational technologies for its SYMBIS™ Surgical System
- a minimally invasive and MRI-compatible microsurgical robot system.
Currently under development at IMRIS, the SYMBIS Surgical System is an
image-guided, micro-neurosurgery robot that will combine
surgeon-directed robotic arm manipulation with integrated
high-definition 3D anatomical and MR imaging views to enable delicate
The system is being designed to work inside an intraoperative MRI within
the VISIUS® Surgical Theatre and provide a virtual extension of the surgeon's hands
through robotic instruments with haptic feedback, motion refinement and
intricate dexterity for use in the narrow surgical pathways of cranial
IMRIS CEO David Graves said this patent represents a fundamental advance
in microsurgical robotics. "SYMBIS has the potential to increase the
consistency and quality of neurosurgery, and when used in conjunction
with the advanced diagnostic imaging capabilities of iMRI, may offer
improvements in patient outcomes compared to current technological and
human limitations," he said. "We will continue to add to our internally
developed and licensed intellectual property portfolio related to
intraoperative imaging and robotics."
The recently allowed US patent - No. 8,396,598 and titled,
"Microsurgical Robot System" - is the fifth patent issued related to
the SYMBIS microsurgical system technology, method and concept since
development of the product began.
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image
guided therapy solutions through its VISIUS Surgical Theatre - a
revolutionary, multifunctional surgical environment that provides
unmatched intraoperative vision to clinicians to assist in decision
making and enhance precision in treatment. VISIUS Surgical Theatres
serve the neurosurgical, cardiovascular and cerebrovascular markets and
have been selected by leading medical institutions around the world.
SOURCE: IMRIS Inc.
For further information: